trial
as of 2026-07-01Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
NCTId NCT02118610
at a glance
— · Completed
Enrollment 63 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2018-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
63 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-09
Primary completion
2018-12
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Indications
Sponsors
University of Maryland, Baltimore CountyLead Sponsor
Stanley Medical Research InstituteCollaborator
Investigators
1
Deanna L. Kelly, Pharm.D., BCPPPrincipal Investigator
Sites
1 total
Catonsville, United States
Facts & assertions
4 sourced
Enrollment
63
Phase
NA
Primary Completion Date
2018-12
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
collaborator
indication
indication
indication
investigator